Clearmind Medicine Inc. (CMND) said that CMND-100, the company's proprietary psychedelic treatment has met the primary endpoint in a Phase I/IIa study in Alcohol Use Disorder (AUD). The stock is up more than 50% in pre-market trading.
The company said the study showed the drug candidate was well tolerated, with no serious adverse events reported in the third cohort and a favorable overall safety profile consistent with earlier cohorts.
Clearmind added that achieving the primary safety and tolerability endpoint, including at higher doses, supports further development of CMND-100 as a potential non-hallucinogenic treatment option for AUD.
Clearmind stock had closed at $0.7196 on Friday, down 13.77%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.